Ignite Creation Date:
2024-05-06 @ 3:08 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04530357
Status:
COMPLETED
Last Update Posted:
2021-05-04
First Post:
2020-08-26
Brief Title:
Reactogenicity Safety and Immunogenicity of QazCovid-in COVID-19 Vaccine
Sponsor:
Research Institute for Biological Safety Problems
Organization:
Research Institute for Biological Safety Problems
Study Overview
Official Title:
Randomized Blind Placebo-controlled Phase- i Study and Randomized Open Phase Phase-ii Study of QAZCOVID-IN- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Randomized blind placebo-controlled phase- i study and randomized open phase phase-ii study of QAZCOVID-IN- COVID-19 inactivated vaccine in healthy adult volunteers from 18 years old and elder
Detailed Description:
Purpose of the Phase-I clinical study Evaluation of the safetyacceptability and immunogenicity of QazCovid-in-COVID-19 inactivated vaccine when administeredtwice in healthy volunteers aged 18-50 years
Purpose of the Phase-II clinical study Evaluation of the safety and immunogenicity of QazCovid-in - COVID-19 inactivated vaccine with single and dual use in healthy volunteers aged 18 and above
Purpose of the Phase-II clinical study Evaluation of the safety and immunogenicity of QazCovid-in - COVID-19 inactivated vaccine with single and dual use in healthy volunteers aged 18 and above
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None